DexCom shares have climbed 52.5% in the past three months, far outpacing the Zacks sub-industry's 18.3% rise, the Zacks Medical sector's 10.4% advance, and the S&P 500's 2.4% increase. Second-quarter 2026 revenues increased 13.1% year over year to $1.31 billion, with adjusted earnings of 70 cents per share beating the Zacks Consensus Estimate of 61 cents. Adjusted gross margin reached 64.1%, up 400 basis points, and adjusted operating margin improved 590 basis points to 25.1%. The stock trades at 30.7 times forward earnings, above the sub-industry's 27.3 times, and faces competition from Abbott and MiniMed Group. DexCom currently carries a Zacks Rank of 3, or Hold.
